Pharmanutra SpA
MIL:PHN
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Mirai Works Inc
TSE:6563
|
JP |
|
Genting Malaysia Bhd
OTC:GMALF
|
MY |
|
Brightspring Health Services Inc
NASDAQ:BTSG
|
US |
|
Corporacion Moctezuma SAB de CV
BMV:CMOCTEZ
|
MX |
|
Harley-Davidson Inc
NYSE:HOG
|
US |
|
S
|
SAH Polymers Ltd
NSE:SAH
|
IN |
|
Americann Inc
OTC:ACAN
|
US |
|
Samsung C&T Corp
KRX:028260
|
KR |
Pharmanutra SpA
Research & Development
Pharmanutra SpA
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Pharmanutra SpA
MIL:PHN
|
Research & Development
-€1.5m
|
CAGR 3-Years
-52%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Intercos SpA
MIL:ICOS
|
Research & Development
-€30.4m
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
N/A
|
|
|
Enervit SpA
MIL:ENV
|
Research & Development
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Pharmanutra SpA
Glance View
Pharmanutra SpA develops nutraceutical products and medical devices. The company is headquartered in Pisa, Pisa. The company went IPO on 2017-07-18. The firm develops nutraceutical products and medical devices. The company focuses on studying and producing formulations that are backed up in scientific research. The company is able to cover all stages of the development of a product, from its design, formulation and registration to its marketing, distribution and training of its commercial representatives. The firm offers Gestalys DHA, a nutritional supplement; Cetilar, a massage coadiuvant, improves and brings relief to joints affected by osteoarthritis; Cetilar patch, a transdermic patch containing a concentrated formulation of cetylated fatty acids (CFA) esters; SiderAL Forte; CardioSiderAL; SiderAL Folico; SiderAL; Bonecal and Novomega, among others.
See Also
What is Pharmanutra SpA's Research & Development?
Research & Development
-1.5m
EUR
Based on the financial report for Sep 30, 2025, Pharmanutra SpA's Research & Development amounts to -1.5m EUR.
What is Pharmanutra SpA's Research & Development growth rate?
Research & Development CAGR 3Y
-52%
Over the last year, the Research & Development growth was 14%. The average annual Research & Development growth rates for Pharmanutra SpA have been -52% over the past three years .
